Viral vector for Gene & Cell Therapy
Pre-clinical and early phase clinical virus production
Guaranteed virus production yields equivalent to R&D grade PEIpro®
Manufactured according to a well-established process
Fully characterized product with extensive Quality Controls
Supplied with appropriate Documentation
Overview
Specifications
Reagent |
PEIpro®-HQ |
Concentration |
1 mg/mL |
Molecule delivered |
Plasmid DNA and co-delivery of several plasmid DNA |
Applications |
Large scale virus production for pre-clinical and early phase clinical trial |
Virus types |
Mainly adenovirus, Adeno-Associated Viruses (AAV), Lentiviral Vector (LV), influenza virus, retrovirus, Virus-Like Particles (VLP) |
Cell types |
Mammalian producer cell lines (HEK-293, HEK-293 derivatives, BHK, VERO cell lines, virus-specific packaging cell lines) grown in adherent or suspension cultures |
Number of transfections |
1 L of PEIpro®-HQ is sufficient to transfect on average 500 L of cell culture |
Storage |
5°C ± 3°C, 3 years from manufacturing date |
Provided with |
Certificate of Analysis |
Regulatory documentation available upon request |
Batch Production Documentation |
Summary
PEIpro®-HQ is a Highly Qualified version of PEIpro® DNA transfection reagent. Large-scale transfection protocols established with PEIpro® during process development are guaranteed to be seamlessly applicable with PEIpro®-HQ for manufacturing of viral vectors for pre-clinical and early phase clinical trial. To move on to therapeutic viral vector production for late phase clinical trials and in fine commercialization, PEIpro®-HQ should be replaced by PEIpro®-GMP, manufactured in compliance with EU “Guidelines of good manufacturing practice for medicinal products for human and veterinary use” (ICH Q7 and EudraLex Vol 4, Part II and Annex I).
Ordering information
Reference Number |
Amount of reagent |
301-100 |
100 ml |
301-01L |
1 L |